Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

The HER2DX genomic test predicts pathological complete response (pCR) and survival outcome in early-stage HER2-positive (HER2+) breast cancer. Here, we evaluated the association of HER2DX scores with (i) pCR according to hormone receptor status and various treatment regimens, and (ii) survival outcome according to pCR status.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Ann Oncol

Title: Annals of oncology : official journal of the European Society for Medical Oncology

Publisher: Elsevier BV

ISSN (Electronic): 1569-8041

ISSN (Print): 0923-7534

Publication date (Electronic): Sep 2023

Volume: 34

Issue: 9

Affiliations

[1 ] SOLTI Breast Cancer Research Group, Barcelona; Oncology Data Science, Vall d'Hebron Institute of Oncology, Barcelona, Spain.

[2 ] Beth Israel, Boston, USA.

[3 ] Medical Oncology Department, Catalan Institute of Oncology, L'Hospitalet de Llobregat, Barcelona.

[4 ] Reveal Genomics, Barcelona.

[5 ] Medical Oncology Department, Hospital Infanta Cristina (Parla), Fundación de Investigación Biomédica del H.U. Puerta de Hierro, Majadahonda, Madrid.

[6 ] Department of Medical Oncology, Hospital General Universitario Gregorio Marañón, Instituto de Investigación Sanitaria Gregorio Marañón, CiberOnc, Madrid.

[7 ] Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.

[8 ] Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA.

[9 ] SOLTI Breast Cancer Research Group, Barcelona; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain.

[10 ] Cancer Genomics Group, VHIO, Barcelona, Spain.

[11 ] Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova; Istituto Oncologico Veneto, IRCCS, Padova, Italy.

[12 ] International Breast Cancer Center, Pangaea Oncology, Quirónsalud Group, Barcelona.

[13 ] Arnau de Vilanova Hospital, Universidad Católica de Valencia, Valencia, Spain.

[14 ] Department of Oncology, Johns Hopkins University School of Medicine, Baltimore.

[15 ] Department of Oncology, University of Pennsylvania, Philadelphia.

[16 ] Lineberger Comprehensive Cancer Center, Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill.

[17 ] Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Harvard Medical School, Boston, USA; Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, USA.

[18 ] Reveal Genomics, Barcelona; Translational Genomics and Targeted Therapies in Solid Tumors, August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Barcelona; Department of Medical Oncology, Hospital Clinic of Barcelona, Barcelona, Spain; Institute of Oncology (IOB)-Quirón, Barcelona, Spain. Electronic address: alprat@clinic.cat.

[19 ] Medical Oncology, Dana-Farber Cancer Institute, Boston; Breast Oncology Program, Dana-Farber Brigham Cancer Center, Boston; Institute of Oncology (IOB)-Quirón, Barcelona, Spain. Electronic address: sara_tolaney@dfci.harvard.edu.

Article

Mid ID: NIHMS1950111 Publisher Item ID: S0923-7534(23)00721-4

DOI: 10.1016/j.annonc.2023.05.012

PMC ID: 10735273

PubMed ID: 37302750

SO-VID: 8b7e8a77-06b8-4ce6-8a1a-12049a8e0adf

History

Keywords: breast cancer,HER2,HER2DX,neoadjuvant,pathological complete response,pertuzumab

Data availability:

Keywords: breast cancer, HER2, HER2DX, neoadjuvant, pathological complete response, pertuzumab

Association of HER2DX with pathological complete response and survival outcomes in HER2-positive breast cancer.

Read this article at

Abstract

Related collections

Karger: Oncology

Author and article information

Journal

Affiliations

Article

History

Comments

Comment on this article

Similar content 354

Cited by 6